Coexpression cluster:C302

Full id: C302_acute_peripheral_Neutrophils_NK_myelodysplastic_CD34_carcinoid

Phase1 CAGE Peaks

Hg19::chr10:134259182..134259198,+	p@chr10:134259182..134259198 +
Hg19::chr10:22603976..22603984,-	p@chr10:22603976..22603984 -
Hg19::chr11:123351501..123351547,+	p@chr11:123351501..123351547 +
Hg19::chr12:125686755..125686767,+	p@chr12:125686755..125686767 +
Hg19::chr12:58230871..58230881,+	p1@ENST00000549683
Hg19::chr12:9886936..9886942,-	p@chr12:9886936..9886942 -
Hg19::chr12:9891753..9891758,-	p@chr12:9891753..9891758 -
Hg19::chr13:52303329..52303347,-	p@chr13:52303329..52303347 -
Hg19::chr14:21359558..21359580,+	p1@RNASE3
Hg19::chr14:21424030..21424062,+	p@chr14:21424030..21424062 +
Hg19::chr14:21424359..21424370,+	p@chr14:21424359..21424370 +
Hg19::chr15:41794867..41794880,+	p@chr15:41794867..41794880 +
Hg19::chr15:57592859..57592869,+	p5@LOC283663
Hg19::chr19:29480252..29480261,-	p@chr19:29480252..29480261 -
Hg19::chr19:3600549..3600592,-	p5@TBXA2R
Hg19::chr1:149157851..149157876,-	p@chr1:149157851..149157876 -
Hg19::chr1:165506847..165506853,+	p@chr1:165506847..165506853 +
Hg19::chr1:200876945..200876972,+	p@chr1:200876945..200876972 +
Hg19::chr1:205899165..205899172,-	p8@SLC26A9
Hg19::chr1:205899180..205899197,-	p3@SLC26A9
Hg19::chr2:135160470..135160480,+	p@chr2:135160470..135160480 +
Hg19::chr3:101504030..101504047,+	p12@FAM55C
Hg19::chr3:126207297..126207316,-	p@chr3:126207297..126207316 -
Hg19::chr3:32896322..32896332,+	p@chr3:32896322..32896332 +
Hg19::chr5:126962527..126962529,-	p@chr5:126962527..126962529 -
Hg19::chr5:448728..448747,+	p@chr5:448728..448747 +
Hg19::chr5:448759..448770,+	p@chr5:448759..448770 +
Hg19::chr5:78011925..78011929,-	p1@ENST00000519121
Hg19::chr7:155156870..155156881,+	p@chr7:155156870..155156881 +
Hg19::chr7:155156893..155156902,+	p@chr7:155156893..155156902 +
Hg19::chr7:155156952..155156963,+	p@chr7:155156952..155156963 +
Hg19::chr7:157464010..157464017,-	p@chr7:157464010..157464017 -
Hg19::chr7:158330152..158330179,+	p1@ENST00000448698
Hg19::chr7:1883150..1883186,-	p@chr7:1883150..1883186 -
Hg19::chr8:141370177..141370224,-	p@chr8:141370177..141370224 -
Hg19::chr8:141370243..141370257,-	p@chr8:141370243..141370257 -
Hg19::chr8:141370262..141370267,-	p@chr8:141370262..141370267 -
Hg19::chr8:141370284..141370289,-	p@chr8:141370284..141370289 -
Hg19::chrX:64818643..64818666,+	p@chrX:64818643..64818666 +
Hg19::chrX:7700640..7700651,+	p@chrX:7700640..7700651 +

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0004961	thromboxane A2 receptor activity	0.00883080183680678
GO:0004960	thromboxane receptor activity	0.024053182288869
GO:0015116	sulfate transmembrane transporter activity	0.024053182288869
GO:0008271	secondary active sulfate transmembrane transporter activity	0.024053182288869
GO:0004522	pancreatic ribonuclease activity	0.024053182288869
GO:0004953	icosanoid receptor activity	0.024053182288869
GO:0004954	prostanoid receptor activity	0.024053182288869
GO:0008272	sulfate transport	0.024053182288869
GO:0016892	endoribonuclease activity, producing 3'-phosphomonoesters	0.024053182288869
GO:0007585	respiratory gaseous exchange	0.024053182288869
GO:0016894	endonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters	0.024053182288869
GO:0006401	RNA catabolic process	0.0337842027341225
GO:0015103	inorganic anion transmembrane transporter activity	0.0452733688192364
GO:0004521	endoribonuclease activity	0.0452733688192364

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

---

Cell Type

Ontology term	p-value	n
hematopoietic stem cell	1.94e-51	172
angioblastic mesenchymal cell	1.94e-51	172
hematopoietic oligopotent progenitor cell	3.85e-48	165
hematopoietic multipotent progenitor cell	3.85e-48	165
hematopoietic cell	6.56e-47	182
leukocyte	6.06e-38	140
myeloid cell	8.17e-35	112
common myeloid progenitor	8.17e-35	112
hematopoietic lineage restricted progenitor cell	1.12e-30	124
nongranular leukocyte	8.44e-30	119
myeloid leukocyte	7.17e-22	76
granulocyte monocyte progenitor cell	7.02e-19	71
myeloid lineage restricted progenitor cell	1.08e-18	70
macrophage dendritic cell progenitor	2.02e-17	65
monopoietic cell	5.83e-17	63
monocyte	5.83e-17	63
monoblast	5.83e-17	63
promonocyte	5.83e-17	63
CD14-positive, CD16-negative classical monocyte	1.86e-14	42
classical monocyte	3.28e-14	45
lymphocyte	1.20e-11	53
common lymphoid progenitor	1.20e-11	53
lymphoid lineage restricted progenitor cell	2.20e-11	52
mesenchymal cell	1.05e-10	358
connective tissue cell	2.02e-10	365
motile cell	2.45e-08	390

Uber Anatomy

Ontology term	p-value	n
hematopoietic system	3.86e-29	102
blood island	3.86e-29	102
hemolymphoid system	4.73e-25	112
bone marrow	7.79e-21	80
bone element	2.46e-19	86
immune system	6.02e-16	115
skeletal element	7.16e-16	101
skeletal system	7.16e-16	101
connective tissue	4.28e-11	375

Disease

Ontology term	p-value	n
hematologic cancer	3.59e-18	51
immune system cancer	3.59e-18	51
leukemia	2.94e-15	39
myeloid leukemia	4.88e-12	31

Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}

ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

---

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

---